Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China
These findings support the potential of belimumab to improve renal and serological parameters, reduce disease activity, lessen corticosteroid dependence, and decrease the risk of TEAEs, demonstrating its safety and efficacy as an adjunct therapy in LN management.
Authors
- Caiming Chen (ORCID: https://orcid.org/0000-0002-8021-6842)
- Zishan Lin (ORCID: https://orcid.org/0000-0003-3513-6939)
- Jianxin Wan (ORCID: https://orcid.org/0000-0002-6733-0472)
- Yanfang Xu (ORCID: https://orcid.org/0000-0002-6207-545X)
- Yujia Wang (ORCID: https://orcid.org/0000-0001-8434-4801)
- Bingjing Jiang
- Wenfeng Wang (ORCID: https://orcid.org/0009-0000-3433-2925)
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2024-09-19
- DOI
- https://doi.org/10.7717/peerj.18028
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- National Natural Science Foundation of China
- Fujian Medical University